BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 21095071)

  • 1. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
    Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
    Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
    Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
    Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience.
    Salama JK; Mell LK; Schomas DA; Miller RC; Devisetty K; Jani AB; Mundt AJ; Roeske JC; Liauw SL; Chmura SJ
    J Clin Oncol; 2007 Oct; 25(29):4581-6. PubMed ID: 17925552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients.
    Vendrely V; Henriques de Figueiredo B; Rio E; Benech J; Belhomme S; Lisbona A; Frison E; Doussau A; Nomikossoff N; Mahé MA; Kantor G; Maire JP
    Radiat Oncol; 2015 Aug; 10():170. PubMed ID: 26268888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.
    Kachnic LA; Winter KA; Myerson RJ; Goodyear MD; Abitbol AA; Streeter OE; Augspurger ME; Schefter TE; Katz AW; Fisher BJ; Henke LE; Narayan S; Crane CH
    Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):146-157. PubMed ID: 34400269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
    Olsen JR; Moughan J; Myerson R; Abitbol A; Doncals DE; Johnson D; Schefter TE; Chen Y; Fisher B; Michalski J; Narayan S; Chang A; Crane CH; Kachnic L
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):400-408. PubMed ID: 28463160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
    Tomasoa NB; Meulendijks D; Nijkamp J; Cats A; Dewit L
    Acta Oncol; 2016 Jun; 55(6):760-6. PubMed ID: 26878244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.
    Mitchell MP; Abboud M; Eng C; Beddar AS; Krishnan S; Delclos ME; Crane CH; Das P
    Am J Clin Oncol; 2014 Oct; 37(5):461-6. PubMed ID: 23466576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
    Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C
    Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
    Troussier I; Huguet F; Servagi-Vernat S; Benahim C; Khalifa J; Darmon I; Ortholan C; Krebs L; Dejean C; Fenoglietto P; Vieillot S; Bensadoun RJ; Thariat J
    Cancer Radiother; 2015 Apr; 19(2):127-38. PubMed ID: 25770884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
    Wright JL; Patil SM; Temple LK; Minsky BD; Saltz LB; Goodman KA
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1064-72. PubMed ID: 20350793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma--clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network.
    DeFoe SG; Beriwal S; Jones H; Rakfal S; Heron DE; Kabolizadeh P; Smith RP; Lalonde R
    Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):424-31. PubMed ID: 22075444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients.
    De Bari B; Jumeau R; Bouchaab H; Vallet V; Matzinger O; Troussier I; Mirimanoff RO; Wagner AD; Hanhloser D; Bourhis J; Ozsahin EM
    Acta Oncol; 2016 Jun; 55(6):767-73. PubMed ID: 27034083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-modulated Radiation Therapy for Anal Cancer: Results From a Multi-Institutional Retrospective Cohort Study.
    Call JA; Prendergast BM; Jensen LG; Ord CB; Goodman KA; Jacob R; Mell LK; Thomas CR; Jabbour SK; Miller RC
    Am J Clin Oncol; 2016 Feb; 39(1):8-12. PubMed ID: 24401669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.
    Hung A; Crane C; Delclos M; Ballo M; Ajani J; Lin E; Feig B; Skibber J; Janjan N
    Cancer; 2003 Mar; 97(5):1195-202. PubMed ID: 12599225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
    Julie DA; Oh JH; Apte AP; Deasy JO; Tom A; Wu AJ; Goodman KA
    Acta Oncol; 2016; 55(2):208-16. PubMed ID: 25984929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
    Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G
    Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):700-7. PubMed ID: 26382849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Anticancer Res; 2016 Apr; 36(4):2027-32. PubMed ID: 27069197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.